BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 969 filers reported holding BAXTER INTL INC in Q3 2017. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $709,836 | -0.3% | 17,372 | +24.9% | 0.22% | -9.7% |
Q4 2022 | $712,130 | +46.8% | 13,908 | +55.1% | 0.25% | +44.2% |
Q3 2022 | $485,000 | +8.0% | 8,969 | +29.0% | 0.17% | +11.7% |
Q2 2022 | $449,000 | -12.5% | 6,954 | +5.4% | 0.15% | +0.7% |
Q1 2022 | $513,000 | -7.4% | 6,598 | +2.6% | 0.15% | +8.5% |
Q4 2021 | $554,000 | +10.6% | 6,429 | +3.5% | 0.14% | +16.5% |
Q3 2021 | $501,000 | +15.7% | 6,213 | +15.9% | 0.12% | +23.5% |
Q2 2021 | $433,000 | -34.5% | 5,361 | -31.4% | 0.10% | -46.2% |
Q1 2021 | $661,000 | +8162.5% | 7,820 | +7566.7% | 0.18% | +5966.7% |
Q1 2019 | $8,000 | +14.3% | 102 | 0.0% | 0.00% | -40.0% |
Q4 2018 | $7,000 | -77.4% | 102 | -74.6% | 0.01% | -54.5% |
Q3 2018 | $31,000 | +3.3% | 401 | 0.0% | 0.01% | 0.0% |
Q2 2018 | $30,000 | +15.4% | 401 | 0.0% | 0.01% | +22.2% |
Q1 2018 | $26,000 | 0.0% | 401 | 0.0% | 0.01% | -10.0% |
Q4 2017 | $26,000 | +4.0% | 401 | 0.0% | 0.01% | 0.0% |
Q3 2017 | $25,000 | +4.2% | 401 | 0.0% | 0.01% | -9.1% |
Q2 2017 | $24,000 | +14.3% | 401 | 0.0% | 0.01% | 0.0% |
Q1 2017 | $21,000 | +16.7% | 401 | 0.0% | 0.01% | +22.2% |
Q4 2016 | $18,000 | – | 401 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |